Premier Asset Management LLC lifted its position in shares of Johnson & Johnson (NYSE:JNJ) by 6.1% in the third quarter, Holdings Channel reports. The institutional investor owned 4,349 shares of the company’s stock after acquiring an additional 249 shares during the period. Premier Asset Management LLC’s holdings in Johnson & Johnson were worth $563,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also recently bought and sold shares of JNJ. Virtus ETF Advisers LLC acquired a new position in Johnson & Johnson in the second quarter valued at about $25,000. Krane Funds Advisors LLC acquired a new position in Johnson & Johnson in the second quarter valued at about $26,000. Financial Advantage Inc. acquired a new position in Johnson & Johnson in the third quarter valued at about $28,000. Crewe Advisors LLC raised its stake in Johnson & Johnson by 725.9% in the second quarter. Crewe Advisors LLC now owns 223 shares of the company’s stock valued at $31,000 after purchasing an additional 196 shares in the last quarter. Finally, Eii Capital Management Inc. acquired a new position in Johnson & Johnson in the third quarter valued at about $39,000. 72.25% of the stock is owned by institutional investors.

NYSE JNJ traded up $1.57 during trading on Friday, hitting $133.00. 4,856,974 shares of the company’s stock were exchanged, compared to its average volume of 7,224,392. The company has a current ratio of 1.26, a quick ratio of 1.00 and a debt-to-equity ratio of 0.46. The company has a market cap of $343.25 billion, a PE ratio of 16.26, a P/E/G ratio of 2.20 and a beta of 0.69. Johnson & Johnson has a fifty-two week low of $121.00 and a fifty-two week high of $148.99. The stock’s 50 day moving average price is $130.83 and its two-hundred day moving average price is $134.05.

Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Tuesday, October 15th. The company reported $2.12 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $2.00 by $0.12. The firm had revenue of $20.73 billion during the quarter, compared to the consensus estimate of $20.14 billion. Johnson & Johnson had a return on equity of 39.81% and a net margin of 21.09%. The business’s quarterly revenue was up 1.9% on a year-over-year basis. During the same quarter in the previous year, the firm earned $2.05 earnings per share. Analysts forecast that Johnson & Johnson will post 8.65 earnings per share for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, December 10th. Shareholders of record on Tuesday, November 26th will be paid a dividend of $0.95 per share. This represents a $3.80 annualized dividend and a yield of 2.86%. The ex-dividend date of this dividend is Monday, November 25th. Johnson & Johnson’s payout ratio is 46.45%.

JNJ has been the subject of a number of analyst reports. Royal Bank of Canada reaffirmed a “buy” rating on shares of Johnson & Johnson in a research note on Tuesday, July 16th. Morgan Stanley reaffirmed an “equal weight” rating and issued a $145.00 price target on shares of Johnson & Johnson in a research note on Tuesday, August 27th. Goldman Sachs Group set a $169.00 price target on Johnson & Johnson and gave the company a “buy” rating in a research note on Tuesday, August 27th. Credit Suisse Group boosted their price target on Johnson & Johnson from $158.00 to $163.00 in a research note on Thursday, October 24th. Finally, Wells Fargo & Co dropped their price target on Johnson & Johnson from $157.00 to $155.00 and set an “outperform” rating for the company in a research note on Wednesday, October 16th. Six equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. Johnson & Johnson presently has a consensus rating of “Buy” and an average price target of $151.64.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

See Also: Why is the ex-dividend date different from the record date?

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.